References
[1] GlobalData’s Top 20 global pharmaceutical companies by market cap (year ended December 31, 2018), GlobalData, 03-05-2019[2] FESE Monthly Statistics Dec 2018, Federation of European Securities Exchanges
[3] Primary Market Summary, Domestic companies, London Stock Exchange Main Market Fact Sheet
[4] Borsa Italiana, Monthly Update, Dec 2018
[5] nasdaq.com, Company list as of 31-12-2018
[6] Market capitalization of listed domestic companies, The World Bank
[7] Is Going Public in Europe the Kiss of Death?, Antoine Papiernik on labiotech.eu, 05-06-0219
[8] ENYO Pharma raises €40 million in Series B fundraising, Enyo Pharma press release, 04-06-2018
[9] Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate, Alizé Pharma press release, 31-07-2019
[10] Another Trophy Quarter For VC-Backed Biotech Funding, Bruce Booth on Forbes.com, 30-04-2018
[11] 2018 biopharma VC & startup report, Bay Bridge Bio
[12] Exploring Company Contributions To The Origination Of New Medicines, Bruce Booth on Forbes.com, 13-10-2016
[13] Better out than in as pharma continues to find value externally, Lisa Urquhart, Evaluate Pharma, 14-03-2017
[14] A year after Hong Kong’s stock listing overhaul, city’s aim to be Asia’s biotech hub is still a work in progress, Enoch Yu, South China Morning Post, 23-04-2019
[15] INVESTMENT BENCHMARK FOR ASIA'S BIOTECHNOLOGY SECTOR: CES HK BIOTECHNOLOGY INDEX, Research Report, HKEX, May 2019
A vast majority of the company level data consolidated in this review are available on our intelligence service (subscription service for pro only). We provide small granularity data, and insights on the main items of biotech investing, for more than 150 companies listed on the main European markets. Disclaimer: we do not provide any investment recommendation on our service. This review is not aimed at supporting an investment decision on any company, any country, or any stock market mentioned in this report. See more details on biotechradar.eu.
The author can be contacted via email, on Twitter @BertrandBio / @biotechradar_eu, or Linkedin.
Frontpage illustration generated on wordclouds.com